Allergan USA Inc.

Allergan USA Inc., a subsidiary of AbbVie Inc., supplies breast implants, tissue expanders, and related surgical devices to the Defense Logistics Agency Medical Supply Chain as a sole-source vendor on fixed-price delivery orders with no set-aside designation. The company operates from Irvine, California and competes entirely in the full-and-open market with 100% prime contract activity across 760 recent federal awards valued at $8.88 billion in combined potential value.

Allergan USA Inc. delivers Natrelle-branded breast implants and tissue expanders—including Inspira, TE Smooth, and Keller Funnel product lines—to military treatment facilities, Veterans Affairs hospitals, and Indian Health Service centers. Representative work includes delivery orders for specific breast implant configurations (SCF 385CC, SSM 310CC, SCM 375CC, TE Smooth 133S variants, and tissue expanders in multiple sizes) awarded by Defense Logistics Agency Medical Supply Chain, most valued between $1,200 and $5,400 per order, with completion dates typically within days or weeks of award. The vendor also supplied a $15,758 prosthetic implant order to Veterans Integrated Service Network 2 on August 28, 2025. All recent awards are fixed-price contracts with economic price adjustment, reflecting the specialized and proprietary nature of these medical devices for which Allergan maintains sole-source status.

Customer concentration is extreme. The Defense Logistics Agency Troop Support Medical dominates the footprint, accounting for 512 awards (67% of the total 760) with $57.4 million in combined potential value. However, a single contract with Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 carries $8.8 billion in potential value, dwarfing all other customer relationships combined and representing the outlier anchor for the $8.88 billion portfolio total. This single VISN 12 award appears to be a framework or master agreement; day-to-day ordering occurs through the DLA vehicle. VA VISNs 7, 8, and 6 place smaller orders in the hundreds of thousands of dollars.

Allergan USA Inc. holds two primary indefinite delivery vehicles with Defense Logistics Agency Troop Support Medical, both established December 8, 2022: a $4.9 million single-award IDC for Allergan Aesthetics surgical items (base period one year, four one-year options, ultimate completion December 7, 2023) and a $13.5 million single-award IDC for Natrelle breast implants and surgical devices (base period one year, four one-year options, ultimate completion November 20, 2027). The $13.5 million vehicle carries 477 task orders representing the overwhelming majority of recent ordering activity, with delivery orders spanning January through April 2026 in the sample. All delivery orders under both vehicles use electronic catalog ordering with on-site Allergan technical support. The company also holds blanket purchase agreements and other smaller IDCs with Army Medical Command and the Air Force that place occasional orders.

Activity has grown sharply. Awards increased from 27 in 2022 to 152 in 2024 and 181 in 2025, with 75 awards recorded in the first portion of 2026. The portfolio is dominated by Laboratory Equipment and Supplies (PSC, 480 awards) and Medical and Surgical Instruments, Equipment, and Supplies (220 awards), with the top NAICS being Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (481 awards) and Surgical Appliance and Supplies Manufacturing (125 awards).

Allergan USA Inc. is a subsidiary of Allergan, Inc. (doing business as Allergan Inc.), a for-profit manufacturer of goods based in Lake Bluff, Illinois. The parent, AbbVie Inc., is a global biopharmaceutical company. Allergan USA Inc. has been registered in SAM since May 22, 2006, and competes as a non-small-business prime contractor. The vendor carries no SBA set-aside designations and operates entirely on full-and-open contract awards, reflecting its market position as the exclusive federal supplier of Natrelle-branded implants and accessories for reconstructive and aesthetic surgical procedures across the federal healthcare system.